Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial
Authors:
Open Access
- 1 August 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 16 (7) , 1529-1537
Abstract
Rasagiline mesylate is a highly potent, selective and irreversible monoamine oxidase type B (MAOB) inhibitor and is effective as monotherapy or adjunct to levodopa for patients with Parkinson's disease (PD). However, few studies have evaluated the efficacy and safety of rasagiline in the Chinese population. This study was designed to investigate the safety and efficacy of rasagiline as adjunctive therapy to levodopa treatment in Chinese PD patients. This was a randomized, double-blind, placebo-controlled, parallel-group, multi-centre trial conducted over a 12-wk period that enrolled 244 PD patients with motor fluctuations. Participants were randomly assigned to oral rasagiline mesylate (1 mg) or placebo, once daily. Altogether, 219 patients completed the trial. Rasagiline showed significantly greater efficacy compared with placebo. During the treatment period, the primary efficacy variable – mean adjusted total daily off time – decreased from baseline by 1.7 h in patients treated with 1.0 mg/d rasagiline compared to placebo (p < 0.05). Scores using the Unified Parkinson's Disease Rating Scale also improved during rasagiline treatment. Rasagiline was well tolerated. This study demonstrated that rasagiline mesylate is effective and well tolerated as an adjunct to levodopa treatment in Chinese PD patients with fluctuations.Keywords
This publication has 23 references indexed in Scilit:
- A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristicsMovement Disorders, 2008
- Rationale for considering that propargylamines might be neuroprotective in Parkinson’s diseaseNeurology, 2006
- Physiology and Pathophysiology of Parkinson's DiseaseAnnals of the New York Academy of Sciences, 2003
- A Controlled Trial of Rasagiline in Early Parkinson DiseaseArchives of Neurology, 2002
- Prevalence of PD and other types of parkinsonism in three elderly populations of central SpainMovement Disorders, 2002
- Mitochondrial permeability transition mediates apoptosis induced by N‐methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl‐2 and rasagiline, N‐propargyl‐1(R)‐aminoindanJournal of Neurochemistry, 2002
- An algorithm (decision tree) for the management of Parkinson’s disease (2001):Neurology, 2001
- Mechanism underlying anti-apoptotic activity of a (−)deprenyl-related propargylamine, rasagilineMechanisms of Ageing and Development, 2000
- Medical Treatment of Later-Stage Motor Problems of Parkinson DiseaseMayo Clinic Proceedings, 1999
- Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivationJournal of Neuroscience Research, 1999